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Replacement of iBAS by beam angle class solutions will be 
discussed as well. 
Conclusion:Automated plan generation, including iBAS, is a 
pre-requisite for systematic, unbiased comparison of the 
impact of beam arrangements in SBRT.  
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Stereotactic Body Radiotherapy (SBRT) involves delivery of a 
high dose with stereotactic precision in only a few fractions. 
Usual treatment sites are lung, liver, spine, prostate and 
often treatment is delivered using a volumetric modulated 
arc therapy (VMAT) technique. With conventional dose rates, 
the highest fraction dose treatments can take 7-12 minutes 
delivery time. This can be reduced to 2-3 minutes by using 
flattening filter free (FFF) beams with dose rates up to 2400 
MU/min. Treatment planning studies have shown similar plan 
quality using FFF or flattened beams. Faster treatments 
implies less time for possible intrafraction motion. However, 
not all measured intrafraction motions could be correlated 
with treatment time. Conversely, due to the fast delivery, 
brief intrafraction shifts may lead to larger dosimetric 
differences than for slower deliveries. In addition, interplay 
effects of a respiratory moving tumor can be larger for the 
faster deliveries. Whether or not all this knowledge can lead 
to margin reduction may also depend on the margins that 
were used and the frequency and accuracy of the imaging. 
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The treatment of cancer with radiopharmaceuticals is 
expanding rapidly in terms of the numbers and range of 
procedures performed. The majority of treatments are 
currently performed with fixed activity administrations, 
sometimes modified according to patient weight or body 
surface area, as  is common practice for chemotherapy 
procedures. Personalised dosimetry-based treatment 
planning, as is routine for external beam radiotherapy 
(EBRT), is now mandated by a new European directive (EU 
directive 2013/59) and presents a number of unique 
challenges. 
There is increasing evidence for strong correlations between 
the absorbed doses delivered to tumours and to organs-at-
risk and response and toxicity (Strigari et al Eur J Nucl Med 
Mol Imaging 2014).  While it is not possible to determine an 
absorbed dose that will be delivered to a tumour or organ 
prior to administration, due to inter-patient variations in 
biokinetics, it is usually found that intra-patient variations 
are much reduced, so that uptake and retention may be 
accurately predicted from a previous therapy study or from a 
tracer study. 
Dosimetry for treatment planning of Molecular Radiotherapy 
(MRT) can be performed with quantitative imaging (SPECT, 
planar or PET) or from external probe measurements. Whole-
body retention measurements allow the calculation of whole-
body dosimetry which, as a surrogate for bone marrow 
dosimetry, has been used for several therapy procedures 
including I-131 mIBG treatment of neuroblastoma in 
paediatrics, uptake measurements for the treatment of 
benign thyroid disease with radioiodine and 
radioimmunotherapy for NHL. Dosimetry based on organ 
dosimetry has been less utilised, although the absorbed doses 
delivered to kidneys are recognised as a limiting factor in 
peptide receptor radionuclide therapy. 
The role of treatment planning is of particular relevance to 
an emerging cohort of commercially driven radiotherapeutics 
and has attracted conflicting approaches. The treatment of 
HCC and liver metastases with intra-arterial injections of 
radiolabelled microspheres has been developed for Y-90 and 
Ho-166 resin and glass microspheres. Initial treatment 
protocols were based on body surface area, although have 
become increasingly sophisticated. Two industry sponsored 
multi-centre international studies are currently in 
preparation to ascertain the correlation of the absorbed 
doses with response on which future treatments would be 
based. Conversely, Ra-223 has recently been at the forefront 
of a new wave of alpha based therapies, although is currently 
administered as a chemotherapeutic with a series of six 
weight-based administrations at 4 week intervals. 
A number of challenges are to be addressed as prospective 
treatment planning is introduced. Tracer administrations I-
131 NaI are considered to cause a ‘stunning’ effect whereby 
further uptake of a therapeutic administration is mitigated, 
although as yet there are no systematic studies to 
demonstrate this effect or its severity. Further, the %ID of 
uptake from a tracer administration will not necessarily 
predict the uptake of a therapeutic administration that may 
be two orders of magnitude higher. This may entail the 
application of correction factors. Further issues to be 
resolved are that patient-specific factors, that may include 
considerations of previous treatments or the time to recovery 
of marrow depression, preclude rigid protocols that will 
necessarily be targeted to the most vulnerable of patients 
and will therefore be sub-optimal for the majority. 
In conclusion, as outstanding challenges are addressed and 
resolved, the ability to directly image the uptake and 
retention of a radiotherapeutic in vivo and the adoption of 
treatment schedules that allow time between sequential 
administrations to calculate the absorbed doses delivered 
and to modify further treatments accordingly, offer the 
potential for highly personalised treatment planning for MRT 
that can only lead to improved efficacy. 
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Bone metastases are a frequent consequence from a wide 
range of malignancies and are associated with a high degree 
of morbidity. More than 90% of patients with metastatic 
castrate resist-ant prostate cancer (mCRPC) have bone 
metastases, often as the only significant metastatic site [1]. 
At diagnosis, approximately10-15% of men presenting with 
prostate cancer have bone metastases at diagnosis. These 
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men will respond to androgen deprivation  therapy for a 
finite time before ultimately progressing and succumbing to 
their disease. 
Bone targeted therapy has included bone-seeking 
radionuclides for nearly 30 years. The beta-emitting bone-
seeking radionuclides Strontium-89 and Samarium-153 EDTMP 
as well as Rhenium-186 HEDP and Rhenium-188 HEDP have 
been used to palliate pain in advanced cancer metastatic to 
bone for many years [2]. Despite clear evidence of benefit in 
palliation, these agents have never been shown to result in a 
survival benefit for patients.  
Radium-223 is the first in class alpha-emitting radionuclide 
which began clinical testing almost 10 years ago and has 
recently become licenced for the treatment of castration 
resistant pros-tate cancer (CRPC) metastatic to bone. In an 
international prospective randomised clinical trial, Radium-
223 (50kBq/kg, for 6 cycles at 4 weekly intervals) + best 
standard of care (BOS) was shown to improve overall survival 
compared to placebo + BOS in men with symptomatic, meta-
static CRPC. Radium-223 also resulted in significant 
improvement in time to symptomatic pro-gression [3].  
The rationale for combining External Beam Radiotherapy 
(EBRT) with Radium-223 in the treatment of metastatic 
prostate cancer will be discussed. In particular the potential 
for using Radium-223 along with advanced EBRT with 
‘curative’ intent in hormone naïve de novo metastatic 
prostate cancer will be described. 
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Throughout the past two decades the efforts to improve 
treatment efficacy for locally advanced head and neck 
squamous cell carcinoma (LA-HNSCC) have led to increased 
use of multimodality approaches combining surgery, 
radiotherapy (RT), and chemotherapy (CT). In fact, 
conventional RT  was associated with unsatisfactory patients’ 
outcomes, thereby a greater understanding of radiobiology 
led to the development of altered irradiation schedules, such 
as hyperfractionation (HF) and accelerated fractionation 
(AF), in the management of advanced HNSCC. Randomized 
controlled trials and meta-analyses demonstrated that for 
patients with locally advanced HNSCC, major improvements 
in loco-regional control and overall survival rates may be 
obtained by AF and HF with increased total radiation dose. 
CT represents an important component of multimodality 
treatment approach for locally advanced HNSCC. The 
combination of concurrent CT and RT (CCRT)  provides a 
substantial and statistically significant improvement in 
survival and loco-regional control, as compared to RT alone. 
CCRT has been also shown to preserve healthy tissue in 
almost two thirds of patients, without affecting survival. 
 However, despite hundreds of clinical trials in patients with 
advanced disease, there is no widespread consensus about 
patient selection for altered fractionation regimens, type of 
chemo-radiotherapy association, radiation/ chemotherapy 
dose schedule in LA-HNSCC. The state of the art of 
radiobiological models for tumor control and toxicity after 
CCRT will be presented together with methods of BED 
calculation. Model parameters will be introduced to be 
applicable to different chemotherapy schedules. The aim is 
to highlight the potential convenience of using radiobiology 
in the selection more effective treatment strategies. As 
secondary aim BED for combined CCRT with/without 
hyperthermia (HT) will be introduced to further stress the 
versatility of radiobiological concepts in predicting patient’ 
outcome and improving the efficacy of treatment strategies. 
 
 
Symposium: Proton therapy, from rationale to planning 
and delivery  
 
 
SP-0370  
Clinical rationale 
S.E. Combs1 
1Klinikum Rechts der Isar, Department of Radiation 
Oncology, Munich, Germany  
   
Particle therapy offers distinct physical properties leading to 
reduction of integral dose. For low-LET particles, biology is 
relatively comparable to photons, however, if this often cited 
sentence is correct in detail, is a matter of discussion. Albeit 
known heterogeneities and differences, altogether, the 
relative biological effectiveness (RBE) is postulated to be 
around 1.1. Proton therapy requires elaborate, large and 
expensive facilities, leading to a cost that is several times 
higher than advanced photon treatments. Treatment planning 
for particle therapy is delicate, special knowledge and 
training is necessary, and caution must be met at all steps. 
In spite of all these challenges, there is a strong rationale 
that the physical benefits of particle therapy convert into a 
clinical benefit for the patient. To date, however, no 
randomized trial has shown these benefits. For certain 
indications, the argument for proton therapy is evident, such 
as some skull base tumors, or pediatric patients, when timely 
proton treatment is available.  
Currently, with many centers worldwide, reserach foci are 
ongoing in different disease groups, as well as in terms of 
further pre-clinical assessment, to define the therapeutic 
window or proton therapy. 
   
SP-0371   
Treatment planning for proton therapy ñ a challenge for 
the whole team 
C. Vallhagen Dahlgren1 
1Skandionkliniken, Skandionkliniken, Uppsala, Sweden  
 
The first Scandinavian Proton Centre, Skandionkliniken, is 
planned to treat its first patient in June 2015; a facility 
owned by the seven regions with university hospitals. 
Patients will be referred to Skandionkliniken through these 
hospitals utilising “distributed competence” [1]. The patients 
will be prepared for treatment at their “home centre”; 
immobilisation, CT-scanning and treatment planning will be 
performed at the university hospital. All treatment plans will 
be reviewed at joint teleconference meetings [2] prior to the 
treatment start. The patient and any individual 
immobilisation device will be sent to Skandionkliniken for 
treatment. Skandionkliniken will be a “spot scanning only” 
facility.  
